Published April 5, 2013 | Edit
EAPH Security Details
Shares Outstanding 87,813,017 a/o Nov 27, 2012
Float 62,811,618 a/o Nov 27, 2012
Authorized Shares 230,000,000 a/o Nov 27, 2012
Par Value 0.0001
Shareholders
Shareholders of Record 198 a/o Nov 27, 2012
Barchart.com has a long term buy recommendation
http://www.barchart.com/opinions/stocks/EAPH
EAPH has been fairly dormant for about a year until recently updating their filings and becoming more transparent, which is a costly process for a small company. After reviewing the recent filings we feel there may be a product launch coming soon. The timing appears to be on target with the chart setting up and increasing daily volume. Here is our due diligence…
Why Invest In Easton Pharmaceuticals and The Woman’s Health care Industry? The world drug market to treat male and female sexual disorders is currently $4.7 billion and expected to grow to $6.6 billion by 2012.
Drug market for sexual disorders is primarily focused on male erectile dysfunction with Viagra, Cialis and Levitra dominating the market. No approved drug options available to treat female sexual arousal disorders in North America and OTC options are ineffective and limited.
Female sexual disorders are estimated to affect 84 million women in the top 7 pharma countries.
US market is estimated at 30-47 million women with hypoactive sexual desire disorder or low sex drive affecting 33.4% of women aged 18-59, difficulty with orgasm 24.1% and 14.4% experiencing pain with intercourse. Premenopausal and menopausal women want to maintain their sexual vitality.
Viorra as an alternative to ineffective hormonal therapies
Millions of women have discovered that traditional hormonal therapies offered by the pharmaceutical industry for the past 50 years are simply not effective in allowing women to enjoy normal sexual pleasure and sensation.
Women do not want to use a ‘drug’ for these conditions. Viorra™ is an over-the-counter topical gel that is safe, effective, and with daily use restores a woman’s vaginal lubricity, and helps improve sensation.
About Easton
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a range of premium, topically delivered therapeutic health care products. The company’s proprietary gel formulation is an innovative and unique transdermal delivery system.
The system is the technology that allows for the rapid development of non-invasive, naturally derived topical solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The transdermal delivery system allows for the targeted delivery of active ingredients, vitamins and herbs through the skin to the underlying tissue.
The company has utilized its transdermal delivery system to develop a safe and effective female sexual enhancement product. The company’s goal is to develop a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: scars and stretch marks, cellulite and varicose veins.
Seeking Alpha Article-mentioning buyout opportunity
Pharmaceuticals offer some of the strongest risk/reward plays. From high dividend yields and inelastic demand to blockbuster drugs and buyout opportunities, they are ideal for both income and aggressive investors. As an IR consultant, I see significant upside potential for Amarillo Bio sciences (AMAR.OB) and Easton Pharmaceuticals (EAPH.PK) off of greater press coverage. They are significantly undervalued and would help catalyze revenue for larger health care firms. (read full article)http://seekingalpha.com/article/447101-why-pfizer-bristol-and-mylan-will-skyrocket
More due diligence links:
http://emergingwomenshealthsolutions.com/
http://www.directglobalmedia.com/wp-content/uploads/2011/09/EAPH_Report.pdf
http://www.lamindustries.com/
As always, you heard it here first and should expect other newsletters to follow suit as the market catches on…
(tagged 2-6 weeks)
